Switch theme
Sign up to access all valuation multiples
Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
1912
179.9K+
LTM Revenue $24.7B
LTM EBITDA $4.0B
$39.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fresenius has a last 12-month revenue (LTM) of $24.7B and a last 12-month EBITDA of $4.0B.
In the most recent fiscal year, Fresenius achieved revenue of $24.5B and an EBITDA of $3.5B.
Fresenius expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fresenius valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.7B | XXX | $24.5B | XXX | XXX | XXX |
| Gross Profit | $6.0B | XXX | $6.0B | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $4.0B | XXX | $3.5B | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $2.8B | XXX | $2.0B | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $1.1B | XXX | $529M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fresenius's stock price is EUR 42 (or $48).
Fresenius has current market cap of EUR 23.9B (or $26.8B), and EV of EUR 35.0B (or $39.3B).
See Fresenius trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39.3B | $26.8B | XXX | XXX | XXX | XXX | $3.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fresenius has market cap of $26.8B and EV of $39.3B.
Fresenius's trades at 1.6x EV/Revenue multiple, and 11.1x EV/EBITDA.
Equity research analysts estimate Fresenius's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fresenius has a P/E ratio of 24.6x.
See valuation multiples for Fresenius and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.8B | XXX | $26.8B | XXX | XXX | XXX |
| EV (current) | $39.3B | XXX | $39.3B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 11.1x | XXX | XXX | XXX |
| EV/EBIT | 13.8x | XXX | 19.6x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.6x | XXX | 50.7x | XXX | XXX | XXX |
| EV/FCF | 21.3x | XXX | 22.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFresenius's last 12 month revenue growth is 5%
Fresenius's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $22K for the same period.
Fresenius's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fresenius's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fresenius and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $22K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fresenius acquired XXX companies to date.
Last acquisition by Fresenius was XXXXXXXX, XXXXX XXXXX XXXXXX . Fresenius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fresenius founded? | Fresenius was founded in 1912. |
| Where is Fresenius headquartered? | Fresenius is headquartered in Germany. |
| How many employees does Fresenius have? | As of today, Fresenius has 179.9K+ employees. |
| Is Fresenius publicy listed? | Yes, Fresenius is a public company listed on ETR. |
| What is the stock symbol of Fresenius? | Fresenius trades under FRE ticker. |
| When did Fresenius go public? | Fresenius went public in 1992. |
| Who are competitors of Fresenius? | Similar companies to Fresenius include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Fresenius? | Fresenius's current market cap is $26.8B |
| What is the current revenue of Fresenius? | Fresenius's last 12 months revenue is $24.7B. |
| What is the current revenue growth of Fresenius? | Fresenius revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Fresenius? | Current revenue multiple of Fresenius is 1.6x. |
| Is Fresenius profitable? | Yes, Fresenius is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fresenius? | Fresenius's last 12 months EBITDA is $4.0B. |
| What is Fresenius's EBITDA margin? | Fresenius's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Fresenius? | Current EBITDA multiple of Fresenius is 9.7x. |
| What is the current FCF of Fresenius? | Fresenius's last 12 months FCF is $1.8B. |
| What is Fresenius's FCF margin? | Fresenius's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Fresenius? | Current FCF multiple of Fresenius is 21.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
